---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157364"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:44:37.896930+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stoke/Biogen present zorevunersen Phase 3 EMPEROR analysis showing cognition/behavior improvements at Week 68

## Summary
- Analysis of patients on EMPEROR-like regimen (2x70mg loading + 2x45mg maintenance) showed cognition/behavior improvements at Week 68.
- Results contrast with natural history (BUTTERFLY) where standard-of-care patients did not show improvements.
- Five Vineland-3 sub-domains (Receptive/Expressive Communication, Interpersonal Relationships, Coping/Personal Skills) added as key secondary endpoints in Phase 3 EMPEROR.
- Data complement prior Phase 1/2a and OLE results showing durable seizure reductions and improvements through two years.
- Zorevunersen is a first-in-class potential disease-modifying RNA medicine for Dravet syndrome co-developed with Biogen.

## SEC filing metadata
- accession: 0001193125-25-157364
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525157364/0001193125-25-157364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525157364/d873782d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157364
- JSON: https://secwatch.observer/filing/0001193125-25-157364.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157364.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.